. 2021 Jun 26;225(3):289.e1–289.e17. doi: 10.1016/j.ajog.2021.05.014

Table 2.

Associations between COVID-19 diagnosis and preeclampsia

Adjustments	All women (n=2075)	Nulliparous (n=901)	Parous (n=1174)
Unadjusted
No COVID-19 diagnosis	Ref	Ref	Ref
COVID-19 diagnosis	1.95 (1.38–2.75)^a	2.20 (1.37–3.55)^a	1.78 (1.08–2.94)^a
No COVID-19 diagnosis	Ref	Ref	Ref
COVID-19 diagnosis, asymptomatic	1.82 (1.14–2.91)^a	2.23 (1.21–4.12)^a	1.46 (0.71–3.02)
COVID-19 diagnosis with symptoms	2.04 (1.37–3.02)^a	2.18 (1.24–3.82)^a	1.98 (1.14–3.46)^a
Demographic adjustment only^b
No COVID-19 diagnosis	Ref	Ref	Ref
COVID-19 diagnosis	2.00 (1.41–2.83)^a	2.14 (1.33–3.44)^a	1.75 (1.06–2.88)^a
No COVID-19 diagnosis	Ref	Ref	Ref
COVID-19 diagnosis, asymptomatic	1.84 (1.15–2.94)^a	2.14 (1.17–3.93)^a	1.53 (0.74–3.16)
COVID-19 diagnosis with symptoms	2.11 (1.42–3.14)^a	2.14 (1.22–3.76)^a	1.88 (1.08–3.27)^a
Full model^c
No COVID-19 diagnosis	Ref	Ref	Ref
COVID-19 diagnosis	1.77 (1.25–2.52)^a	1.89 (1.17–3.05)^a	1.64 (0.99–2.73)^d
No COVID-19 diagnosis	Ref	Ref	Ref
COVID-19 diagnosis, asymptomatic	1.70 (1.07–2.72)^a	1.99 (1.07–3.71)^a	1.46 (0.71–3.00)
COVID-19 diagnosis with symptoms	1.81 (1.22–2.70)^a	1.81 (1.04–3.16)^a	1.75 (0.99–3.08)^d

The total numbers reflect the number of participants with complete outcome and covariate data in the final models.

Ref, reference group.

Papageorghiou et al. Preeclampsia and COVID-19. Am J Obstet Gynecol 2021.

P<.05

Adjusted for maternal age, previous parity (nulliparous vs parous), tobacco use during pregnancy, and history of adverse pregnancy outcomes

Adjusted for maternal age, previous parity (nulliparous vs parous), tobacco use during pregnancy, overweight status (normal, underweight, overweight, or obese), or history of diabetes, cardiac disease, hypertension, kidney disease, or adverse pregnancy outcomes

P<.1.